证券代码：688139 证券简称：海尔生物 公告编号：2026-005 青岛海尔生物医疗股份有限公司 关于股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何 虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性依法承担法律责任。 重要内容提示： 股东持股基本情况 2.为严格履行公司回购股份方案中关于回购股份使用期限的相关承诺，同时增强投资者回报能力和水平， 切实维护广大投资者利益，公司将第一次回购计划存放于回购专用账户中的 1,459,586 股已回购股份用途 由"用于员工持股计划或股权激励"变更为"用于注销并相应减少注册资本"并已于 2026 年 1 月 6 日注销 完成。 2 青岛海创睿股权投资基金中心（有限合伙）（以下简称"海创睿"）持有青 岛海尔生物医疗股份有限公司（以下简称"公司"或"海尔生物"）32,103,659 股，占公司总股本的 10.14%。该股份属于公司首次公开发行前取得的股份，截 至本公告披露日，上述股东所持股份均已上市流通。 海创睿与公司实际控制人海尔集团公司（以下简称"海尔集团"）签署了《表 决权委托协议》，构成一致行动关系。此外，海尔 ...

Core Viewpoint - Haier Bio received a notice from Haichuang Rui regarding a share reduction plan due to its own funding needs, indicating a potential impact on the company's stock performance [1] Group 1: Share Reduction Plan - Haichuang Rui plans to reduce its shareholding in Haier Bio through centralized bidding, with a maximum reduction of 0.85% of the total share capital, equivalent to no more than 2,690,189 shares [1] - The reduction period is set to begin 15 trading days after the announcement of this reduction plan and will last for three months [1] - The reduction price will be determined based on market prices [1]

证券代码：688139 证券简称：海尔生物 公告编号：2026-005 青岛海尔生物医疗股份有限公司 关于股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何 虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性依法承担法律责任。 重要内容提示： 股东持股基本情况 青岛海创睿股权投资基金中心（有限合伙）（以下简称"海创睿"）持有青 岛海尔生物医疗股份有限公司（以下简称"公司"或"海尔生物"）32,103,659 股，占公司总股本的 10.14%。该股份属于公司首次公开发行前取得的股份，截 至本公告披露日，上述股东所持股份均已上市流通。 海创睿与公司实际控制人海尔集团公司（以下简称"海尔集团"）签署了《表 决权委托协议》，构成一致行动关系。此外，海尔集团还通过其控制的青岛海尔 生物医疗控股有限公司（以下简称"海尔生物医疗控股"）以及一致行动人青岛 海创智管理咨询企业（有限合伙）（以下简称"海创智"）分别持有公司股份 100,591,463 股和 8,675,900 股，占公司总股本的 31.78%、2.74%。 海尔集团一致行动人海创智分别于 2022 年 3 月、2 ...

Group 1 - The core point of the article is that Qingdao Haichuangrui Equity Investment Fund Center (Limited Partnership), a shareholder holding 10.14% of Haier Bio, plans to reduce its stake by up to 2.6902 million shares, which represents 0.85% of the company's total share capital, due to funding needs [1] - The reduction period is set from March 3, 2026, to June 2, 2026, and the shareholder currently holds 32.1037 million shares, all acquired before the IPO [1] - As of the announcement date, the actual controller and concerted parties collectively hold 141 million shares, accounting for 44.67%, and have not reduced their holdings since the company's listing, indicating that the reduction plan will not lead to a change in control [1]

Core Viewpoint - Haier Biomedical aims to become a world-class brand in life sciences trusted by global users, with a focus on expanding its business internationally and enhancing its industry presence [1] Group 1: Business Expansion - The company has expanded its operations to over 150 countries and regions worldwide [1] - Localized deployments have been established in 18 countries [1] - Revenue from overseas markets now accounts for more than 35% of total income [1] Group 2: Strategic Focus - Haier Biomedical is committed to a strategy of both organic growth and external acquisitions within the life sciences sector [1] - The company plans to identify high-quality targets in the life sciences industry to strengthen its existing operations and broaden its business scope [1] - There is an emphasis on entering high-potential market segments [1]

Group 1 - The core point of the article is that Haier Biomedical has reported a total of 14,022 shareholders as of January 20, 2026 [1]

Core Viewpoint - Haier Biomedical is committed to aligning management interests with company development and shareholder value, establishing a compensation system that matches market development, operational performance, and sustainable growth [1] Summary by Relevant Sections Management Compensation - The company has developed a management compensation system that is compatible with market development and aligns with both company performance and individual achievements [1] Investor Returns - Haier Biomedical has implemented continuous dividends for six consecutive years since its listing, with a total dividend payout of 788 million RMB. The dividend ratio for the 2024 fiscal year has been increased to 40.31% [1] - The actual controller's concerted action parties have increased their holdings in the company three times, with a total investment of approximately 384 million RMB [1] - The company has initiated three rounds of share repurchase plans, with a total repurchase amount of about 250 million RMB, and has canceled 1.4596 million shares from the repurchased stock on January 6, 2026 [1] Regulatory Compliance - The company emphasizes regulatory operations and diligently fulfills its information disclosure obligations, stating that there is currently no undisclosed information [1]

Core Viewpoint - Haier Biomedical has achieved significant growth in its overseas market, with over 35% of its total revenue coming from international sales, and a year-on-year growth of 20% expected in the first three quarters of 2025 [2] Group 1: Overseas Market Performance - The company has reported high double-digit growth in the European region, contributing to its overall overseas revenue increase [2] - The growth in overseas business is attributed to the company's localized operational system and the continuous expansion of its product categories [2] Group 2: Localization Strategy - Haier Biomedical has established localized operations in 18 countries and set up subsidiaries in the UK, Netherlands, and other locations [2] - The company focuses on understanding local user needs and employs localized planning, marketing, warehousing, and services to address core user pain points [2] Group 3: Brand Development - The company aims to become a globally trusted brand in life sciences, with a significant increase in overseas revenue, achieving a compound annual growth rate of over 20% from 2016 to 2024 [2] - Haier Biomedical's business now covers over 150 countries and regions worldwide, showcasing its extensive market reach [2]

Core Viewpoint - Haier Biomedical aims to replicate the successful overseas acquisition strategy of Haier Smart Home in the medical device industry, focusing on high-potential sectors and global expansion [2]. Group 1: Company Strategy - Haier Biomedical, a subsidiary of Haier Group, is focused on becoming a world-class brand in life sciences, with operations in over 150 countries and regions [2]. - The company has achieved localized deployment in 18 countries, with overseas market revenue accounting for over 35% of total income [2]. Group 2: Future Plans - Haier Biomedical will continue to seek high-quality targets in the life sciences industry to enhance its existing business and expand its operational boundaries [2]. - The company emphasizes compliance with legal regulations and timely information disclosure as part of its strategic approach [2].

Core Viewpoint - Haier Biomedical's subsidiary, Haier Blood Technology Chongqing Co., Ltd., has received the first EU MDR certification for its plasma separation equipment, marking a significant milestone for the company in expanding its market presence in Europe and globally [2][5]. Group 1: Certification and Compliance - The MDR compliance assessment is a prerequisite for medical devices entering the EU market, ensuring product safety, performance, and post-market surveillance [5]. - The successful certification of Haier's plasma separation equipment demonstrates the company's adherence to EU regulations in product design, manufacturing, and quality control [5]. Group 2: Company Statements and Future Plans - Haier Biomedical's General Manager, Liu Zhanjie, emphasized that obtaining the MDR certificate is a recognition of the company's quality management system and positions Haier Blood Technology to compete globally [7]. - The company aims to leverage this certification as a new starting point to promote Chinese manufacturing solutions in global healthcare [7]. Group 3: TÜV Rheinland's Role - TÜV Rheinland serves as a notified body for EU medical device regulations, providing compliance assessments and certifications that enhance the competitiveness of "Made in China" products in international markets [8]. Group 4: Company Overview - Haier Blood Technology Chongqing Co., Ltd. was established in 2001 and specializes in comprehensive solutions for blood and blood component collection, processing, testing, storage, transportation, and usage [8]. - The company's main products include plasma separation machines, disposable centrifuge plasma separators, and various types of blood bags and related medical devices [8].